Table 1 Ongoing clinical trials using AAT in young patients with type 1 diabetes
From: Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option?
NCT | Phase | Age range (years) | Source/dose of AAT (mg) |
|---|---|---|---|
01304537 | II | 10 to 25 | Glassia®/40-60-80 |
01319331 | I | 6 to 45 | Aralast NP |
01183468 | II | 8 to 35 | Aralast NP |